Published online Dec 26, 2020. doi: 10.4252/wjsc.v12.i12.1529
Peer-review started: June 29, 2020
First decision: September 24, 2020
Revised: October 7, 2020
Accepted: November 11, 2020
Article in press: November 11, 2020
Published online: December 26, 2020
Processing time: 180 Days and 8 Hours
Mesenchymal stem cells (MSCs) are the most frequently used stem cells in clinical trials due to their easy isolation from various adult tissues, their ability of homing to injury sites and their potential to differentiate into multiple cell types. However, the realization that the beneficial effect of MSCs relies mainly on their paracrine action, rather than on their engraftment in the recipient tissue and subsequent differentiation, has opened the way to cell-free therapeutic strategies in regenerative medicine. All the soluble factors and vesicles secreted by MSCs are commonly known as secretome. MSCs secretome has a key role in cell-to-cell communication and has been proven to be an active mediator of immune-modulation and regeneration both in vitro and in vivo. Moreover, the use of secretome has key advantages over cell-based therapies, such as a lower immunogenicity and easy production, handling and storage. Importantly, MSCs can be modulated to alter their secretome composition to better suit specific therapeutic goals, thus, opening a large number of possibilities. Altogether these advantages now place MSCs secretome at the center of an important number of investigations in different clinical contexts, enabling rapid scientific progress in this field.
Core Tip: Mesenchymal stem cells (MSCs) produce a high number of bioactive molecules and extracellular vesicles, known as secretome, which exerts important paracrine effects on neighbouring cells and tissues. The use of MSCs secretome in tissue regeneration therapies would circumvent the problems linked to MSCs-based therapies, such as low cell survival and engraftment, which importantly limit their therapeutic efficacy, or the negative side effects associated with the administration of these cells.